BRAF and colonic neoplasm: While mutant BRAF was shown to be among Hsp90 several clients, Hsp90 inhibition failed to abolish mutant BRAF in colon cancer, suggesting that it may not be solely, nor heavily dependent on Hsp90 for its stabilization [92,93].